Get Instant Stock Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
NewAmsterdam Pharma Company N.V. Warrant (NASDAQ : NAMSW) Stock
MWN-AI** Summary
MWN-AI** Analysis
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Description
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Quote
| Last: | $10.41 |
|---|---|
| Change Percent: | -13.25% |
| Open: | $10.74 |
| Close: | $10.41 |
| High: | $10.74 |
| Low: | $10.41 |
| Volume: | 720 |
| Last Trade Date Time: | 10/06/2026 01:24:46 pm |
Stock Data
| Market Cap: | $3,968,678,140 |
|---|---|
| Float: | 62,439,780 |
| Insiders Ownership: | N/A |
| Institutions: | 35 |
| Short Percent: | N/A |
| Industry: | Biotechnology & Life Sciences |
| Sector: | Healthcare |
| Website: | https://www.newamsterdampharma.com |
| Country: | NL |
| City: | Naarden |
Recent News Releases
Subscribe to Our Newsletter
**MWN-AI FAQ is based on asking OpenAI questions about NewAmsterdam Pharma Company N.V. Warrant (NASDAQ: NAMSW).
